Back to Search
Start Over
Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
- Source :
- Chronic Diseases and Translational Medicine, Vol 5, Iss 3, Pp 155-169 (2019)
- Publication Year :
- 2019
- Publisher :
- Wiley, 2019.
-
Abstract
- Current cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs. Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies. In this review, we summarized the current understanding with THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), which demonstrated promising anti-tumor activity against different cancer types. By introducing the anti-tumor behaviors and the potential targets for different cancers, this review aims to provide more effective approaches to CDK7 inhibitor-based therapeutic agents and deeper insight into the diverse tumor proliferation mechanisms. Keywords: THZ1, Cyclin-dependent kinase 7, Cancer therapy, Transcription, Super-enhancer
- Subjects :
- Medicine (General)
R5-920
Subjects
Details
- Language :
- English
- ISSN :
- 2095882X
- Volume :
- 5
- Issue :
- 3
- Database :
- Directory of Open Access Journals
- Journal :
- Chronic Diseases and Translational Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.65a4a41082d4663a0cc81b8d4f5703e
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.cdtm.2019.08.006